Pharma Update

HY 2023: Strong momentum for key growth drivers Vabysmo Ocrevus Hemlibra Evrysdi Phesgo Tecentriq Polivy Perjeta Tamiflu TNKase/Activase Gazyva Alecensa Enspryng Xolair Lunsumio Xofluza Ronapreve Actemra/RoActemra MabThera Herceptin 15% 20% 48% 69% 12% 114% 9% 298% 15% 22% 10% 56% 4% n/a >500% 2% -6% -17% -19% -21% -46% US ■Europe >500% Roche ■Japan Avastin Lucentis International Esbriet -73% -400-300-200 -100 0 100 200 300 400 500 600 700 800 900 1,000 47 Absolute values and growth rates at Constant Exchange Rates (CER)

View entire presentation